Barbara is SVP, General Counsel of Senda Biosciences, overseeing all corporate legal and intellectual property operations at the company. Barbara has deep experience leading and advising life sciences companies on various legal matters relating to corporate governance, business development, licensing, financing, securities law, intellectual property, and regulatory matters.
Prior to joining Senda, Barbara was at BridgeBio Pharma, Inc., where she was most recently Vice President, Head of Legal. While at BridgeBio Pharma, Barbara supported key activities in connection with the commercialization of the company’s first two FDA-approved drugs, NULIBRY® (fosdenopterin) and TRUSELTIQ® (infigratinib). Barbara transitioned in-house from Goodwin Procter LLP, where she was a member of the firm’s Tech & Life Sciences Group. While at Goodwin, Barbara led BridgeBio Pharma’s $400.8 million initial public offering and completed a secondment to Moderna, Inc., as its interim Senior Corporate Counsel. Prior to joining Goodwin, Barbara was a corporate associate at Cooley LLP where she was a member of the public companies and emerging companies practice groups. Barbara joined Cooley as part of a 13-person Capital Markets team from Reed Smith LLP, where she commenced her career.
Barbara received a B.A. from the University of Pennsylvania and a J.D. from Cornell Law School.